NEW YORK (GenomeWeb News) – Cantor Fitzgerald on Monday initiated coverage of molecular diagnostics firm Trovagene with a Buy rating and a $10 price target on the company's stock.

In a research report, analyst Sung Ji Nam said that the San Diego-based firm's technology platform is capable of analyzing systemic cell-free DNA and RNA isolated from urine and could be used as a non-invasive diagnostic with applications across multiple disease areas and health conditions, including cancer, infectious diseases, transplant medicine, and prenatal diagnostics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.